myBiometry raises funding to advance development of fenoTRACK device
The funding round was led by Dexcom Ventures and saw contributions from CareSource Indiana and Elevate Ventures and others.
MyBiometry has secured a $5m investment in an oversubscribed seed funding round to propel the development of its fenoTRACK device for asthma and chronic obstructive pulmonary disease (COPD). The funding round was spearheaded by Dexcom Ventures and saw contributions from Elevate Ventures and CareSource Indiana, among other investor groups. This financial boost is set to advance the fenoTRACK technology, a portable device that aims to empower patients with critical data for the early detection of exacerbations. fenoTRACK operates as a non-invasive breath test that quantifies type 2 airway inflammation by measuring fractional exhaled nitric oxide (FeNO).
